A systematic review of RCTs and quasi-RCTs on traditional Chinese patent medicines for treatment of chronic hepatitis B

Journal of Traditional Chinese Medicine

Volumn 31, Issue 4, 2011, Pages 288-296

  Zhan, Tao ^a   Wei, Xing ^a   Chen, Ze Qi ^a   Wang, Dong Sheng ^a   Dai, Xing Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Quality of clinical trials; Systematic review; Traditional Chinese patent medicines

Indexed keywords

ALANINE AMINOTRANSFERASE; AN LUO HUA XIAN; ASPARTATE AMINOTRANSFERASE; CAO XIAN YI GAN; CHINESE DRUG; COLLAGEN TYPE 4; DA HUANG ZHE CHONG; DANG FEI LI GAN NING; FU FANG KU SHEN; FU GAN KANG; FU ZHENG HUA YU; GAN FU KANG; GAN SHU; GAN SU; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HUANG QI; HYALURONIC ACID; LAMININ; LIU WEI WU LING; PROCOLLAGEN; PROCOLLAGEN TYPE 3; QIANG GAN; QING GAN LI DAN; QING KAI LING; SALVIA MILTIORRHIZA EXTRACT; SHUANG HU QING GAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WU LING DAN; YE XIA ZHU; ANTIVIRUS AGENT; HERBACEOUS AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINA; CHINESE MEDICINE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CAPSULE; DRUG EFFICACY; DRUG GRANULE; DRUG HYPERSENSITIVITY; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER HISTOLOGY; MORTALITY; NAUSEA; PATENT; PILL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SYMPTOM; SYSTEMATIC REVIEW; TABLET; TREATMENT OUTCOME; REVIEW;

ANTIVIRAL AGENTS; DRUGS, CHINESE HERBAL; HEPATITIS B, CHRONIC; HUMANS; PATENTS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860592189     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0254-6272(12)60006-5     Document Type: Article

References (36)

1. Lai CL, Yuen MF. Chronic Hepatitis B - New Goals, New Treatment. N Engl J Med 2008; 359: 2488-2491.
2. Liu JP, H McIntosh, Lin H. Chinese medicinal herbs for chronic hepatitis B. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001940. DOI:10.1002/14651858.CD001940.
3. Cynthia Levy, Leonard D. Seeff and Keith D. Lindor. Use of herbal supplements for chronic liver diseases. Clinical Gastroenterology and Hepatology 2004; 11: 947-956.
4. Stickel F, Schuppan D. Herbal medicines in the treatment of liver diseases. Dig Liver Dis 2007; 39: 293-304.
5. Guidelines on prevention and treatment of chronic hepatitis B in China (2005). Chinese Medical Journal 2007; 120: 2159-2173.
6. Cui-xiang Jin, Jing Yang, Hai-Feng Sun, Wang Q. Comparative Study of the Clinical Effects of Salvia Miltiorrhiza Injection and Sheng Mai Injection for Chronic Hepatitis B. Chinese Journal of Integrated Traditional and Western Medicine (Chin) 2006; 26: 936-938.
7. Yu ZG. Observation on Shuang Hu Qing Gan granule in the treatment of liver fibrosis in patients with chronic hepatitis B. Chin J of Clinical Rational Drug Use (Chin) 2009; 16: 7-8.
8. Hou XJ, Tang XP. Clinical Observation on Chronic Hepatitis B Treated with Chinese Traditional Medicine Shuang Hu Qing Gan Granule. Chinese General Practice (Chin) 2007; 10: 1190-1192.
9. Shu XQ. Observation on the patients with chronic hepatitis B treated with Shuang Hu Qing Gan granule plus Lamivudine. Journal of Bethune Military Medical College (Chin) 2006; 4: 100-101.
10. Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, et al. A multicenter clinical trial on Fu Zheng Hua Yu Capsule for treating liver fibrosis in chronic hepatitis B patients. J Chin Integr Med (Chin) 2003; 1: 89-102.
11. Liang GL. A report of 32 patients with liver fibrosis induced by chronic hepatitis B treated with Compound Ku Shen injection. Guangxi Medical Journal (Chin) 2004; 26: 1628-30.
12. Xiao ZH. A report of 40 patients with jaundice induced by chronic hepatitis B treated with Shu Gan Ning injection. Fujian Journal of Traditional Chinese Medicine (Chin) 2009; 40: 15-16.
13. Qi TJ, Xu CJ, Li J, Xu J. Clinical observation on patients with chronic hepatitis B treated with Wu Ling Dan capsule. Beijing Journal of Traditional Chinese Medicine (Chin) 2009; 28: 545-546.
14. Yang YT, Sha Q. A clinical report of 100 patients with chronic hepatitis B treated with Ao Tai Le granule. Chin J Ctrl Endem Dis (Chin) 2003; 18: 184-185.
15. Zhang SJ, Mao XJ, Shao Y, Cao C. A clinical trial on Shuang Hu Qing Gan granule for the treatment of chronic hepatitis B. Infect Dis Info (Chin) 2005; 18: 28-30.
16. Qiu ZH, Zhang XM, Yan XH, Lan JZ, Luo JW. Clinical observation on135 patients with chronic hepatitis B treated with Shuang Hu Qing Gan granule. Fujian Med J (Chin) 2006; 28: 133-135.
17. Cheng SJ, Nie ZY, Wei H. A manufacturing technology study and clinical trial on Gan Shu capsule. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine (Chin) 2002; 12: 118-119.
18. Zhang BZ, Ding F, Chen LP, Zuo H, Tan LW, Peng QZ. Experimental and clinical study of Yi Gan Ning granule for treatment of chronic hepatitis B. Chinese Journal of Integrative Medicine (Chin) 1993; 13: 597-599.
19. Horie Y, Kikuchi M, Yamagishi Y, Umeda R, Ebinuma H, Saito H, et al. Effect of a herbal medicine on fatty liver in rats fed ethanol chronically. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2009; 44(6): 636-48
20. Yuxian X, Feng T, Ren L, Zhengcai L. Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori 2009; 95: 789-795.
21. Che XH, Park EJ, Zhao YZ, Kim WH, Sohn DH. Tanshinone II A induces apoptosis and S phase cell cycle arrest in activated rat hepatic stellate cells. Basic Clin Pharmacol Toxicol 2010; 106: 30-37.
22. Park EJ, Zhao YZ, Kim YC, Sohn DH. Preventive effects of a purified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and in vivo. Food Chem Toxicol 2009; 47: 2742-2748.
23. Liang R, Helge Bruns1, Marius Kincius, Lin T, Jochen Ludwig, Genevieve Dei-Anane, et al. Danshen protects liver grafts from ischemia/reperfusion injury in experimental liver transplantation in rats. Transpl Int 2009; 22: 1100-1109.
24. Susan T Goldstein, Fangjun Zhou, Stephen C Hadler, Beth P Bell, Eric E Mast, Harold S Margolis. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-39.
25. Li HY, Cui L, Cui M. Hot topics in Chinese herbal drugs research documented in PubMed/MEDLINE by authors inside and outside of China in the past 10 years: based on co-word cluster analysis. J Altern Complement Med 2009; 15: 779-785.
26. Chen SB, Chen SL, Xiao PG. Ethnopharmacological investigations on Thalictrum plants in China. J Asian Nat Prod Res 2003; 5: 263-271.
27. Qin GW, Xu RS. Recent advances on bioactive natural products from Chinese medicinal plants. Med Res Rev. 1998; 18(6): 375-82
28. Arianne P Verhagen, Henrica C.W de Vet, Robert A de Bie, Maarten Boers, Piet A van den Brandt. The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol 2001; 54: 651-654.
29. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess 2003; 7: 1-90.
30. Lawson ML, Pham B, Klassen TP, Moher D. Systematic reviews involving complementary and alternative medicine interventions have higher quality of reporting than conventional medicine reviews. J Clin Epidemiol 2005; 58: 777-784.
31. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
32. Wu TX, Li YP, Bian ZX, Liu GJ, David Moher. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009; 46(10): 10-18.
33. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10: 459-479.
34. Jiangshan Wang, Rob van der Heijden, Shannon Spruit, Thomas Hankermeier, Kelvin Chan, Jan van der Greef, et al. Quality and safety of Chinese herbal medicines guided by a systems biology perspective. J Ethnopharmacol 2009; 126: 31-41.
35. Singhuber J, Zhu M, Prinz S, Kopp B. Aconitum in traditional Chinese medicine: a valuable drug or an unpredictable risk? J Ethnopharmacol 2009; 126: 18-30.
36. Yuen MF, Tam S, Fung J, DKH Wong, Wong BCY, Lai CL. Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment Pharmacol Ther 2006; 24(8): 1179-1186.